Publication Authors:
Park, Y.J.; Choi, I.Y.; Trautmann, M.E.; Hompesch, M; Sorli, C.H.
Poster presented at 54th European Association for the Study of Diabetes (EASD) Annual Meeting, Berlin, Germany, October, 2018.
About this Poster:
Efpeglenatide, a long-acting glucagon-like peptide-1 receptor agonist in development for type 2 diabetes, induces weight loss through satiety and reduced food intake. Studies in Sprague Dawley rats investigated how peripheral and central mechanisms contribute to the anorectic effects of efpeglenatide.
